Image-guided radiation therapy developer ViewRay posted a substantial increase in revenue for its 2018 fiscal second quarter but also a steeper net loss.
For the quarter (end-June 30), total revenue reached $16.4 million, compared with only $0.7 million for the same period in 2017. Three new installations of its MR image-guided radiation therapy system, MRIdian Linac, contributed to this growth.
ViewRay's net loss of $26.2 million -- up from $1.2 million for the same quarter last year -- was marked by an increase in total operating expenses.
